{
    "id": 18691,
    "fullName": "HIF1A positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "HIF1A positive indicates the presence of the HIF1A gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3091,
        "geneSymbol": "HIF1A",
        "terms": [
            "HIF1A",
            "bHLHe78",
            "HIF-1-alpha",
            "HIF-1A",
            "HIF-1alpha",
            "HIF1",
            "HIF1-ALPHA",
            "MOP1",
            "PASD8"
        ]
    },
    "variant": "positive",
    "createDate": "02/25/2016",
    "updateDate": "04/01/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4760,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, EZN-2968 treatment resulted in decreased HIF-1A mRNA level in 33% (4/6) of patients with advanced solid tumors, and prolonged stabilization of disease (24 weeks) in a patient with duodenal neuroendocrine tumor (PMID: 24292632).",
            "molecularProfile": {
                "id": 19045,
                "profileName": "HIF1A positive"
            },
            "therapy": {
                "id": 3612,
                "therapyName": "EZN-2968",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4704,
                    "pubMedId": 24292632,
                    "title": "Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1\u03b1), in patients with refractory solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24292632"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9003,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilenya (fingolimod) sensitized a Hif1a and Epas1(Hif2a)-expressing renal clear cell carcinoma cell line xenograft model to Gemzar (gemcitabine), resulting in decreased tumor volume (PMID: 27507852).",
            "molecularProfile": {
                "id": 26654,
                "profileName": "EPAS1 pos HIF1A pos"
            },
            "therapy": {
                "id": 4857,
                "therapyName": "Fingolimod + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6849,
                    "pubMedId": 27507852,
                    "title": "FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27507852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9002,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Gilenya (fingolimod) resulted in a transient decrease in expression of Hif1a and Epas1 (Hif2a), circulating VEGF levels, remodeling of blood vessels, reduced proliferation, and increased tumor cell death, but was not associated with significant tumor growth inhibition in a VHL wild-type renal clear cell carcinoma cell line xenograft model (PMID: 27507852).",
            "molecularProfile": {
                "id": 26654,
                "profileName": "EPAS1 pos HIF1A pos"
            },
            "therapy": {
                "id": 3610,
                "therapyName": "Fingolimod",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6849,
                    "pubMedId": 27507852,
                    "title": "FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27507852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19045,
            "profileName": "HIF1A positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26654,
            "profileName": "EPAS1 pos HIF1A pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}